ZA88382B - Stabilized compositions - Google Patents

Stabilized compositions

Info

Publication number
ZA88382B
ZA88382B ZA88382A ZA88382A ZA88382B ZA 88382 B ZA88382 B ZA 88382B ZA 88382 A ZA88382 A ZA 88382A ZA 88382 A ZA88382 A ZA 88382A ZA 88382 B ZA88382 B ZA 88382B
Authority
ZA
South Africa
Prior art keywords
stabilized compositions
stabilized
saccharide
coloration
cyclization
Prior art date
Application number
ZA88382A
Other languages
English (en)
Inventor
Michael Harris
Harris Michael
Gerard Hokanson
Hokanson Gerard
Kuchi Murthy
Murthy Kuchi
Robert Reisch
Reisch Robert
Frank Waldman
Waldman Frank
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21785512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA88382(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA88382B publication Critical patent/ZA88382B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
ZA88382A 1987-02-24 1988-01-20 Stabilized compositions ZA88382B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/017,962 US4743450A (en) 1987-02-24 1987-02-24 Stabilized compositions

Publications (1)

Publication Number Publication Date
ZA88382B true ZA88382B (en) 1989-09-27

Family

ID=21785512

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA88382A ZA88382B (en) 1987-02-24 1988-01-20 Stabilized compositions

Country Status (13)

Country Link
US (1) US4743450A (da)
EP (1) EP0280999B1 (da)
JP (1) JP2619904B2 (da)
AT (1) ATE84210T1 (da)
AU (1) AU597471B2 (da)
CA (1) CA1300510C (da)
DE (1) DE3877226T2 (da)
DK (1) DK169593B1 (da)
HK (1) HK59496A (da)
IE (1) IE60931B1 (da)
NZ (1) NZ223407A (da)
PH (1) PH26279A (da)
ZA (1) ZA88382B (da)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
ATE112491T1 (de) 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
US5238935A (en) * 1991-05-20 1993-08-24 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
US5124337A (en) * 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
FR2665834B1 (fr) * 1991-07-24 2001-02-23 Sandoz Sa Composition pharmaceutique stabilisee par un donneur d'acide chlorhydrique, et sa preparation.
TW284688B (da) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5573780A (en) * 1995-08-04 1996-11-12 Apotex Usa Inc. Stable solid formulation of enalapril salt and process for preparation thereof
US6296871B1 (en) 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
ES2242398T3 (es) 1998-06-05 2005-11-01 Warner-Lambert Company Llc Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US20030027837A1 (en) * 1998-12-08 2003-02-06 Sherman Bernard Charles Pharmaceutical compositions comprising quinapril magnesium
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US6637359B1 (en) * 1998-12-15 2003-10-28 Maritrans Inc. System and method for internally fitting a new inner hull to an existing outer hull to form a rebuilt double hull vessel
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6764694B1 (en) * 1999-08-31 2004-07-20 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US6555551B1 (en) 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2303481A1 (en) * 2000-04-05 2001-10-05 Bernard Charles Sherman Pharmaceutical compositions comprising moexipril magnesium
US6333332B1 (en) * 2000-08-25 2001-12-25 Impax Laboratories, Inc. Stabilized pharmaceutical compositions containing bupropion hydrochloride
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
EA007981B1 (ru) * 2002-01-15 2007-02-27 Актавис Груп Хф. Фармацевтический состав, содержащий хинаприл или фармацевтически приемлемую его соль
US20050202081A1 (en) * 2002-01-15 2005-09-15 Deepak Bahl Stable pharmaceutical compositions comprising ace inhibitor(s)
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
AU2003270245A1 (en) * 2003-09-23 2005-04-11 Texcontor Etablissement Stable quinapril compositions
US20050181055A1 (en) * 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
EP1694308A1 (en) * 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
EP1734931A2 (en) * 2004-03-24 2006-12-27 Actavis Group Formulations of ramipril
LT1729739T (lt) * 2004-03-29 2016-11-10 Les Laboratoires Servier Kietos farmacinės kompozicijos gamybos būdas
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
GR1006875B (el) * 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
RU2429878C2 (ru) 2005-11-17 2011-09-27 Силверстоун Фарма Ист Стабильная композиция аморфных солей периндоприла, способ ее получения, в частности промышленного получения, и ее применение в терапии гипертензии
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
US7943655B2 (en) * 2006-04-05 2011-05-17 Universitat Zurich Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007264414A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ACE inhibitors
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
BRPI0815405A2 (pt) * 2007-08-17 2015-02-03 Boehringer Ingelheim Int Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
JP2009084242A (ja) * 2007-10-02 2009-04-23 Nichi-Iko Pharmaceutical Co Ltd 安定性に優れた塩酸テモカプリル錠剤
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2009113081A1 (en) * 2008-03-10 2009-09-17 Lupin Limited Tris (hydroxymethyl ) amino methane salt of quinapril and ramipril
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UA119131C2 (uk) * 2008-08-15 2019-05-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Похідні пурину для застосування при лікуванні пов'язаних із fab захворювань
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
DK2468281T3 (da) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig farmaceutisk sammensætning
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
EP2585051B2 (en) * 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
DK2731947T3 (da) 2011-07-15 2019-04-23 Boehringer Ingelheim Int Substitueret dimerisk quinazolin-derivat, fremstilling og andvendelse deraf i farmaceutiske sammensætninger til behandling af type i- og type ii-diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
EP3038465B1 (en) 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016015798A1 (en) 2014-07-31 2016-02-04 Pharmathen S.A. Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2017077425A1 (en) 2015-11-07 2017-05-11 Ftf Pharma Private Limited Oral solution of ace inhibitors
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422176A (en) * 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
US4255413A (en) * 1979-10-01 1981-03-10 Smithkline Corporation Gelatin capsule dosage unit containing triamterene
EP0170775B2 (de) * 1981-12-29 1994-10-12 Hoechst Aktiengesellschaft Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung
US4584299A (en) * 1984-05-21 1986-04-22 Warner-Lambert Company Method of treating heart failure and medicaments therefor
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH06104680B2 (ja) * 1985-11-13 1994-12-21 株式会社大塚製薬工場 プロリン誘導体
DE3610391A1 (de) * 1986-03-27 1987-10-08 Hoechst Ag Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen

Also Published As

Publication number Publication date
DE3877226D1 (de) 1993-02-18
DK94088D0 (da) 1988-02-23
AU1130588A (en) 1988-08-25
IE60931B1 (en) 1994-09-07
JPS63225322A (ja) 1988-09-20
EP0280999A2 (en) 1988-09-07
PH26279A (en) 1992-04-10
HK59496A (en) 1996-04-12
EP0280999A3 (en) 1988-11-17
ATE84210T1 (de) 1993-01-15
US4743450A (en) 1988-05-10
JP2619904B2 (ja) 1997-06-11
AU597471B2 (en) 1990-05-31
CA1300510C (en) 1992-05-12
EP0280999B1 (en) 1993-01-07
DK169593B1 (da) 1994-12-19
DE3877226T2 (de) 1993-04-29
DK94088A (da) 1988-08-25
IE880142L (en) 1988-08-24
NZ223407A (en) 1989-08-29

Similar Documents

Publication Publication Date Title
ZA88382B (en) Stabilized compositions
AU7939787A (en) Drug compositions stabilized against oxidation
AU7927487A (en) Stabilized drug compositions
AU625542B2 (en) Dominant amylose-extender mutant of maize
AU2163388A (en) Flame treatment
FI880036A0 (fi) Munvaordsprodukt.
EP0244189A3 (en) Human pancreatic elastase i
GB2199746B (en) Stabilization of antibiotic compositions with salts.
AU597632B2 (en) 2-oxo-1-(substituted phosphorous) azetidines
EP0307730A3 (en) Expression of mutarotase
AU3031689A (en) Tris-kringle plasminogen activator with novel k2 insert